Structure Therapeutics Inc. recorded two insider transactions over the past ninety days, totaling approximately 1.85 million dollars in proposed sales. These divestments by officers occurred following an August results report that missed earnings expectations. The stock has experienced a 23.6 percent decline during this period, reflecting broader market volatility for the healthcare firm.